Microvesicle Technology (Carisome™)

Caris Life Sciences' Carisome™ platform represents a revolution in blood-based diagnostics, prognostics, and therapeutic guidance to aid clinicians and their patients with treatment decisions. Caris is pioneering major advances in the understanding of blood-based circulating microvesicles (cMV) and their application to patient care, through more accurate diagnosis and therapeutic planning.^1,2,3

Using a novel, proprietary, patent-pending platform, Caris is able to rapidly and accurately identify and characterize disease-associated circulating microvesicles from the blood. This disruptive, next generation clinical platform has direct clinical utility in early diagnostic testing, disease monitoring, and therapeutic response.